Interferon-beta1
Biologic (subtype unspecified)
Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.
Evidence outlook
No clinical trials on ClinicalTrials.gov
No clinical trial of this drug is registered on ClinicalTrials.gov, so there is nothing to grade. Studies run outside that registry are not tracked here.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
No investor-visible indication is recorded for this drug.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
No registered studies of this drug's own program.
Appears in other studies (1)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 2 (1)
What this study did
Competitive landscape
Other Type I interferon receptor drugs
Interferon alfa-2b (Intron A), Interferon beta-1b, peginterferon alfa-2a (Pegasys), peginterferon beta-1a, Rebif (interferon beta 1a) and 2 more. Compare all 8 Type I interferon receptor drugs
7 other tracked programmes target this mechanism.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Interferon-Beta1: this drug | Stage not on record | Biologic (subtype unspecified) | Type I interferon receptor | not yet graded | No reviewed efficacy summary | |
| Interferon Alfa-2b (Intron A) | Approved(overall) | Biologic (subtype unspecified) | Type I interferon receptor | Partial signal | NCT01359956: Overall survival, interferon alfa-2b added vs not added to dacarbazine-based chemotherapy (2x2 factorial): HR 0.92 (95% CI 0.70 to 1.20), p=0.68 (Daponte et al., J Transl Med 2013). missed | |
| Interferon Beta-1b | Approved(overall) | Biologic (subtype unspecified) | Interferon beta receptor (type I IFN signaling), Type I interferon receptor | Partial signal | NCT00185211: Time to Clinically Definite Multiple Sclerosis (CDMS) Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS at Selected Points in Time (up to 60 months after start of treatment): Initial IFNB-1b (Interferon Beta-1b) — Kaplan-Meier estimate at year 2: 26.9 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 3: 36.7 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 5: 46.2 cum. percentage of particip. with CDMS vs Initial Placebo — Kaplan-Meier estimate at year 2: 45 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 3: 51.2 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 5: 57.3 cum. percentage of particip. with CDMS NCT00099502: Enrolled 897 (250mcg) + 899 (500mcg) + 448 (glatiramer acetate) = 2244 patients (matches this trial's enrollment). Annualized relapse rate 0.33-0.36 across arms; no statistically significant difference in relapse/progression measures between the 500mcg and 250mcg IFN beta-1b doses, or vs glatiramer acetate. missed | |
| Peginterferon Alfa-2a (Pegasys) | Approved(overall) | — | Type I interferon receptor | Partial signal | NCT00006164: Long-term peginterferon did not reduce the rate of disease progression vs no treatment in chronic hepatitis C with advanced fibrosis missed | |
| Peginterferon Beta-1a (Plegridy) | Approved(overall) | Biologic (subtype unspecified) | Type I interferon receptor, Interferon beta receptor (type I IFN signaling) | Reliable signal | NCT00906399: Annualized Relapse Rate (ARR) at 1 Year (1 Year): Year 1: Peginterferon Beta-1a Q4W 0.288 relapses per person-years (95% CI 0.234 to 0.355) | Year 1: Peginterferon Beta-1a Q2W 0.256 relapses per person-years (95% CI 0.206 to 0.318) vs Year 1: Placebo 0.397 relapses per person-years (95% CI 0.328 to 0.481) NCT01939002: New or increased FLS during the first 8 weeks: 10.3% overall versus 25% null (p<0.0001); current FLS therapy 13% versus naproxen 7.4% (p=0.2037). | |
| Rebif (interferon Beta 1a) | Approved(overall) | Biologic (subtype unspecified) | Interferon beta receptor (type I IFN signaling), Type I interferon receptor | Weak signal | Featured results are non-efficacy only | |
| Ropeginterferon Alfa-2b (Besremi) | Approved(overall) | Protein / enzyme therapeutic | Type I interferon receptor | Partial signal | NCT04285086: Durable modified ELN response at months 9 and 12: 39 (43%) of 91 ropeginterferon alfa-2b vs five (6%) of 83 anagrelide | |
| Human Serum Albumin / Interferon Alpha2b Fusion Protein | Phase 1/2(overall) | Biologic (subtype unspecified) | Type I interferon receptor | not yet graded | No reviewed efficacy summary |
Upcoming events
No upcoming readouts on record for this asset.